These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 10549572)

  • 21. Immunotoxins containing A-chain of mistletoe lectin I are more active than immunotoxins with ricin A-chain.
    Tonevitsky AG; Agapov II; Shamshiev AT; Temyakov DE; Pohl P; Kirpichnikov MP
    FEBS Lett; 1996 Aug; 392(2):166-8. PubMed ID: 8772196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond.
    Ghetie V; Thorpe P; Ghetie MA; Knowles P; Uhr JW; Vitetta ES
    J Immunol Methods; 1991 Sep; 142(2):223-30. PubMed ID: 1717600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The chronic lymphocytic leukemia antigen (cCLLa) as immunotherapy target: assessment of LD50 and MTD of four ricin-based anti-cCLLa immunotoxins (ITs) in Balb/c mice.
    Faguet GB; Agee JF
    Leuk Lymphoma; 1997 May; 25(5-6):531-7. PubMed ID: 9250824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells.
    Zhou XX; Ji F; Zhao JL; Cheng LF; Xu CF
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1266-75. PubMed ID: 20594254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin.
    Wawrzynczak EJ; Watson GJ; Cumber AJ; Henry RV; Parnell GD; Rieber EP; Thorpe PE
    Cancer Immunol Immunother; 1991; 32(5):289-95. PubMed ID: 1998970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin.
    Uckun FM; Myers DE; Irvin JD; Kuebelbeck VM; Finnegan D; Chelstrom LM; Houston LL
    Leuk Lymphoma; 1993 Apr; 9(6):459-76. PubMed ID: 7687916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Preparation of SOKT1-RTA immunotoxin and its specific cytotoxic effect on human T lymphocytes].
    Zhong W; Dai B
    Hua Xi Yi Ke Da Xue Xue Bao; 1991 Sep; 22(3):240-4. PubMed ID: 1748404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation and characterization of an anti-CD19 single-chain Fv immunotoxin composed of C-terminal disulfide-linked dgRTA.
    Wang D; Li Q; Hudson W; Berven E; Uckun F; Kersey JH
    Bioconjug Chem; 1997; 8(6):878-84. PubMed ID: 9404661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New coupling reagents for the preparation of disulfide cross-linked conjugates with increased stability.
    Arpicco S; Dosio F; Brusa P; Crosasso P; Cattel L
    Bioconjug Chem; 1997; 8(3):327-37. PubMed ID: 9177838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ricin A-chain cytotoxicity depends on its presentation to the cell membrane.
    Carayon P; Bord A; Gaillard JP; Vidal H; Gros P; Jansen FK
    Bioconjug Chem; 1993; 4(2):146-52. PubMed ID: 7533001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
    Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the cytotoxic effect of hormonotoxins prepared with the use of heterobifunctional cross-linking agents N-succinimidyl 3-(2-pyridyldithio)propionate and N-succinimidyl 6-[3-(2-pyridyldithio)propionamido]hexanoate.
    Singh V; Mavila AK; Kar SK
    Bioconjug Chem; 1993; 4(6):473-82. PubMed ID: 8305517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The activity of two immunotoxins composed of monoclonal antibody MoAb-16 and A-chain of ricin (MoAb-16-RTA) or A-chain of mistletoe lectin I (MoAb-16-MLIA).
    Paprocka M; Wiedłocha A; Walzel H; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1992; 40(3-4):223-7. PubMed ID: 1300987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization.
    Fulton RJ; Tucker TF; Vitetta ES; Uhr JW
    Cancer Res; 1988 May; 48(9):2618-25. PubMed ID: 3258546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.
    Liu XY; Pop LM; Schindler J; Vitetta ES
    MAbs; 2012; 4(1):57-68. PubMed ID: 22327430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thiol-containing cross-linking agent with enhanced steric hindrance.
    Greenfield L; Bloch W; Moreland M
    Bioconjug Chem; 1990; 1(6):400-10. PubMed ID: 2129154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds.
    Ramakrishnan S; Bjorn MJ; Houston LL
    Cancer Res; 1989 Feb; 49(3):613-7. PubMed ID: 2783383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction and increase of HLA-DR antigen expression by immune interferon on ML-3 cell line enhances the anti-HLA-DR immunotoxin activity.
    Chiron M; Jaffrezou JP; Carayon P; Bordier C; Roubinet F; Xavier C; Brandely M; Laurent G
    Clin Exp Immunol; 1990 Nov; 82(2):214-20. PubMed ID: 2122930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blocking effect of human serum but not of cerebrospinal fluid on ricin A chain immunotoxin potentiation by monensin or carrier protein-monensin conjugates.
    Candiani C; Franceschi A; Chignola R; Pasti M; Anselmi C; Benoni G; Tridente G; Colombatti M
    Cancer Res; 1992 Feb; 52(3):623-30. PubMed ID: 1732050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative biochemical, cytotoxic and pharmacokinetic properties of immunotoxins made with native ricin A chain, ricin A1 chain and recombinant ricin A chain.
    Wawrzynczak EJ; Cumber AJ; Henry RV; Parnell GD
    Int J Cancer; 1991 Jan; 47(1):130-5. PubMed ID: 1985869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.